These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29635472)

  • 21. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
    Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ; Marchillo K; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses.
    Bremmer DN; Balada-Llasat JM; Goff DA; Bauer KA
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):192-194. PubMed ID: 28291629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone.
    Winans SA; Luce AM; Hasbun R
    Infection; 2013 Aug; 41(4):769-74. PubMed ID: 23686435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci by applying contemporary in-vitro results and pharmacokinetic-pharmacodynamic principles.
    Sader HS; Bhavnani SM; Ambrose PG; Jones RN; Pfaller MA
    J Chemother; 2007 Feb; 19(1):38-43. PubMed ID: 17309849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of cefazolin inoculum effect-positive methicillin-susceptible staphylococcus aureus infection in a multicentre bacteraemia cohort.
    Song KH; Jung SI; Lee S; Park S; Kiem SM; Lee SH; Kwak YG; Kim YK; Jang HC; Kim YS; Kim HI; Kim CJ; Park KH; Kim NJ; Oh MD; Kim HB;
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):285-294. PubMed ID: 27714592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an
    Werth BJ; Shireman LM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.
    Roberts JA; Udy AA; Jarrett P; Wallis SC; Hope WW; Sharma R; Kirkpatrick CM; Kruger PS; Roberts MS; Lipman J
    J Antimicrob Chemother; 2015 May; 70(5):1495-502. PubMed ID: 25608584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens.
    Song X; Long M
    Int J Clin Pharm; 2018 Oct; 40(5):1059-1071. PubMed ID: 30117081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
    Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW
    Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Test for the Rapid Detection of the Cefazolin Inoculum Effect in Methicillin-Susceptible Staphylococcus aureus.
    Rincon S; Carvajal LP; Gomez-Villegas SI; Echeverri AM; Rios R; Dinh A; Pedroza C; Ordoñez KM; Nannini E; Sun Z; Fowler VG; Murray BE; Miller WR; Palzkill T; Diaz L; Arias CA; Reyes J
    J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Tsuji BT; Rybak MJ
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2735-45. PubMed ID: 15980344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of fosfomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Graninger W; Leitha T; Havel M; Georgopoulos A
    Infection; 1984; 12(4):293-5. PubMed ID: 6092279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics.
    Tsuji BT; Harigaya Y; Lesse AJ; Forrest A; Ngo D
    J Chemother; 2013 Feb; 25(1):32-5. PubMed ID: 23433442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
    Li J; Echevarria KL; Traugott KA
    Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion To Treat an External Ventricular Drainage-Related
    Grégoire M; Gaborit B; Deschanvres C; Lecomte R; Deslandes G; Dailly É; Ambrosi X; Bellouard R; Asseray N; Lakhal K; Boutoille D
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.